AstraZeneca : Update on CRYSTALIZE evidence trials - Form 6-K -December 01, 2023 at 06:29 am EST

a2725v

FORM 6-K


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549


Report of Foreign Issuer


Pursuant to Rule 13a-16 or...

Related Keywords

China ,Japan ,Denmark ,Washington ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Danish ,Sharon Barr ,Coll Cardiol ,Adrian Kemp ,Securities Exchange ,Nasdaq ,European Medicines Agency Lokelma ,Company Secretary ,Astrazeneca ,Astrazeneca Pharmaceuticals ,Investor Relations Team ,Diabetes Work Group ,Commission File Number ,Foreign Issuer ,Securities Exchange Act ,File Number ,Crick Avenue ,Regulationst Rule ,Outcomes Phase ,Executive Vice President ,Rare Diseases ,Dialysate Potassium Concentrations ,Clinj Am Soc ,Single Number ,Communication Worldwide More ,Individuals Have Kidney ,Nephrol Dial ,Global Burden ,Disease Study ,Heart Failure ,American College ,American Heart Association Joint Committee ,Clinical Practice ,Improving Global Outcomes ,Diabetes Work ,Treatment Gap Between Clinical Guidelines ,Renin Angiotensin Aldosterone System ,Trials Gov ,Sodium Zirconium Cyclosilicate ,Chronic Kidney Disease ,Participants With ,Arrythmia Related Cardiovascular Outcomes ,Chronic Hemodialysis With Recurrent Hyperkalemia ,Medicines Agency ,Product Characteristics ,Markets ,